(ARTL) Artelo Biosciences, Inc. Business Model Canvas Research

Artelo Biosciences, Inc. depends on manufacturing and formulation partners for ART12.11, a synthetic cannabidiol cocrystal, and for ART27.13 and ART26.12, which are synthetic or small-molecule programs. External teams help make clinical-grade material and generate stability data needed for IND-ready development.

• Qualified CMO and analytics support
• Clinical-grade batches and release testing
• Stability data for shelf-life
• Lower internal capex and faster scale-up

Artelo Biosciences, Inc. relies on capital market stakeholders because it is still funding clinical development, not product sales. Like most development-stage biotech issuers, it has used equity financing to support R and D and multi-year trials, while recent filings show continuing losses and cash burn that make outside capital essential.

• Equity markets fund R and D
• Investors bridge pre-commercial losses
• Financing supports multi-year trials

Artelo Biosciences, Inc. must keep IND files, safety reports, and quality records aligned with FDA and other agency rules; for serious, unexpected adverse events, IND safety reports are typically due within 15 calendar days. Strong quality systems protect trial integrity, reduce protocol drift, and keep future approval paths credible.

• Maintain IND and safety reporting
• Track FDA and agency compliance
• Protect data quality and study integrity
• Support future approval readiness

Artelo Biosciences, Inc. must keep investors and partners updated with clear science reads, trial milestones, and financing plans through SEC filings, press releases, and data updates. As a clinical-stage company with no product revenue, this communication is central to securing partnership interest and funding for ongoing development.

• Share trial data fast and clearly
• Explain financing needs early
• Use updates to support partnerships

Artelo Biosciences, Inc. relies on scientific and regulatory know-how to turn cannabinoid biology into clinical data, especially across IND-enabling work, protocol design, and trial management. In 2025, that mattered because the company remained clinical-stage and had to translate discovery assets into human data with tight FDA and execution discipline.

• Deep cannabinoid biology expertise
• Regulatory filing and IND skills
• Trial execution for clinical data

Artelo Biosciences, Inc., founded in 2011 and based in Solana Beach, California, uses its public-company status as a key resource for funding and investor access. As a listed development-stage biotech, it can tap equity markets to support research, clinical work, and operations while keeping a visible corporate presence for partners and capital providers.

• Founded in 2011
• Headquartered in Solana Beach, California
• Public listing helps financing access
• Supports development-stage operations

Artelo Biosciences, Inc. uses ART12.11 and ART26.12 to reach more than oncology, including inflammatory bowel disease and PTSD, so the company is not tied to one market. With two lead assets across three indication areas, the odds improve that at least one program can find a clear clinical niche and support future value creation.

• Two assets, broader indication reach
• Oncology, IBD, and PTSD coverage
• Higher chance of one niche win

Artelo Biosciences, Inc. focuses on synthetic compounds, not botanical products, so it can control purity, dose, and batch-to-batch consistency more tightly. That matters for clinical development and scale-up, since reproducible chemistry is easier to test, manufacture, and file for commercialization.

• More consistent dosing
• Easier manufacturing scale-up
• Better support for clinical trials

Artelo Biosciences, Inc. manages a formal, continuous FDA and ethics-committee link for its development-stage therapeutics, with ongoing IND submissions, protocol changes, and safety reports. In clinical trials, serious adverse events can trigger 7-day or 15-day reporting windows, so the relationship stays compliance driven and tightly documented.

• IND filings and protocol alignment
• 7- or 15-day SAE reporting
• Continuous regulator contact

Artelo Biosciences, Inc. must keep close ties with oncologists, gastroenterologists, psychiatrists, and cachexia experts because these specialists drive trial referrals and later adoption. Cancer cachexia affects 50% to 80% of patients with advanced cancer, so scientific credibility and clear clinical data are central to every conversation.

• Target referral-driving specialists
• Build trust with clinical evidence
• Support adoption in cachexia care

Artelo Biosciences, Inc. uses medical conference presence to place its data in front of clinicians, researchers, and potential partners, which is key for pipeline credibility. In biopharma, scientific meetings like ASCO and AACR can drive near-term visibility, and the segment remains high value: congress sponsorship and travel are small vs. R&D spend, but they can shape trial awareness and deal flow.

• Reaches key opinion leaders fast
• Builds trust in early data
• Supports partnering discussions

Artelo Biosciences, Inc. uses its corporate website and SEC filings to share pipeline updates, strategy, and financial disclosures in one place. These channels are low-cost and always on, so investors can review 10-K, 10-Q, and 8-K data anytime and do faster due diligence.

• Always available to stakeholders
• Low distribution cost
• Supports due diligence
• Shares pipeline and financial data

Oncology clinicians and care centers are key gatekeepers for Artelo Biosciences, Inc.: they steer prescribing, trial enrollment, and site selection, even though they are not the end users today. In 2025, cancer burden stayed huge at about 20 million new cases and 9.7 million deaths worldwide, so physician trust and center feedback will matter for future commercialization.

• Drive prescribing and trial enrollment
• Shape site access and adoption
• Feedback informs future launch plans

Artelo Biosciences, Inc. targets pharmaceutical and biotech partners for development, licensing, and co-development because these buyers want differentiated molecules and human clinical data. This B2B segment matters when a pipeline has 1 or more assets with proof-of-concept, since partners often pay for speed, risk share, and IP access.

• Differentiated molecules
• Clinical data
• Licensing and co-dev deals

Artelo Biosciences, Inc. keeps regulatory and legal costs high because drug work needs FDA filings, compliance, patent protection, and SEC reporting before any revenue starts. For a clinical-stage biotech, these fixed costs rise with each milestone, since every new trial step adds counsel, review work, and IP updates.

• FDA filings and trial compliance
• Patent and IP defense
• SEC reporting and audit support
• Costs rise at each milestone

Artelo Biosciences, Inc.’s general and administrative expenses cover public-company finance, audit, insurance, investor relations, and HQ overhead, and they fund the operating base around the pipeline. In a small biotech, this line often stays high even before product revenue, because the company still must run reporting, compliance, and capital-markets work.

• Finance, audit, insurance, IR

• HQ and corporate overhead

• Supports the pipeline platform

Artelo Biosciences, Inc. can use grant and other non-dilutive funding to help pay for translational and clinical work, especially early-stage programs where cash burn is high and equity raises are expensive. Non-dilutive capital does not add new shares, so it helps limit shareholder dilution while keeping development moving.

• Funds early R&D without new equity.
• Best fit for translational and clinical studies.
• Supports programs before partnering or revenue.

Artelo Biosciences, Inc. can create future revenue by out-licensing assets, collecting upfront fees, development milestones, and later royalties if a partnered program reaches market. This is a standard biotech model; in its latest filings, Artelo still had no product sales, so licensing cash could be a key non-dilutive funding source.

• Upfront cash can fund R&D
• Milestones track clinical progress
• Royalties scale only after launch